ALB and neoplasm: Low-dose chemotherapy (e.g., albumin-bound paclitaxel) decreases immune-suppressive cell infiltration (such as regulatory T cells), promoting tumor antigen release and dendritic cell maturation, thereby improving the efficacy of PD-1 monoclonal antibodies.